(Q38104287)

28 August 2017

title

To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century (English)

1 reference

28 August 2017

C Ustun

1

1 reference

28 August 2017

H M Lazarus

series ordinal

2

1 reference

28 August 2017

D Weisdorf

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

6 May 2013

1 reference

Bone Marrow Transplantation

28 August 2017

published in

1 reference

28 August 2017

volume

48

1 reference

28 August 2017

issue

12

1 reference

28 August 2017

page(s)

1497-1505

1 reference

Acute myelogenous leukemia in older adults

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Survival for older patients with acute myeloid leukemia: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Acute myeloid leukemia in the real world: why population-based registries are needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Age and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Can reduced-intensity allogeneic transplantation cure older adults with AML?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Impact of previous aspergillosis on the outcome of bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Is it time to revisit standard post-remission therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Cord-blood engraftment with ex vivo mesenchymal-cell coculture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Future of cord blood for oncology uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

Impairment in functional status and survival in patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

Estimating clinically significant differences in quality of life outcomes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization f

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.67

7 January 2021

Identifiers

DOI

10.1038/BMT.2013.67

1 reference

Dimensions Publication ID

28 August 2017

1041088615

0 references

Fatcat ID

release_qxf4mqblp5ee5duyd3pkea4w2e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qxf4mqblp5ee5duyd3pkea4w2e

24 November 2022

mapped directly with Wikidata item

1 reference